Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Marine Maurel, Jennifer Howard, Esther Kissling, Francisco Pozo, Gloria Pérez‐Gimeno, Silke Buda, Noémie Sève, Adele McKenna, Adam Meijer, Ana Paula Rodrigues, Iván Martínez‐Baz, Ivan Mlinarić, Neus Latorre‐Margalef, Gergő Túri, Mihaela Lazăr, Clara Mazagatos, Aitziber Echeverría, Stephen Abela, Marc Bourgeois, Ausenda Machado, Ralf Dürrwald, Goranka Petrović, Beatrix Oroszi, Ligita Jančorienė, Alexandru Marin, Petr Husa, Róisín Duffy, Frederika Dijkstra, Virtudes Gallardo García, Luise Goerlitz, Vincent Enouf, Charlene Bennett, Mariëtte Hooiveld, Raquel Guiomar, Camino Trobajo‐Sanmartín, Vesna Višekruna Vučina, Tove Samuelsson Hagey, A. Azevedo, Jesús Castilla, Gerd Xuereb, Bénédicte Delaere, Verónica Gomez, Kristin Tolksdorf, Sabrina Bacci, Nathalie Nicolay, Marlena Kaczmarek, Angela Rose, on behalf of the European IVE group
Abstract
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.